Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
Zhang J, Huang M, Cai Y, Wang L, Xiao J, Lan P, Hu H, Wu X, Ling J, Peng J, Chen D, Kang L, Zhang Y, Ren D, Wang H, Chen S, Lin F, Zheng J, Zhou Z, Wang J, Deng Y. Zhang J, et al. Among authors: hu h. Clin Colorectal Cancer. 2019 Dec;18(4):238-244. doi: 10.1016/j.clcc.2019.07.001. Epub 2019 Jul 11. Clin Colorectal Cancer. 2019. PMID: 31378655 Clinical Trial.
Nomogram for predicting pathological complete response and tumor downstaging in patients with locally advanced rectal cancer on the basis of a randomized clinical trial.
Zhang JW, Cai Y, Xie XY, Hu HB, Ling JY, Wu ZH, Lan P, Wu XJ, Huang MJ, Wang H, Kang L, Zhou ZY, Wang JP, Deng YH. Zhang JW, et al. Among authors: hu hb. Gastroenterol Rep (Oxf). 2020 Feb 8;8(3):234-241. doi: 10.1093/gastro/goz073. eCollection 2020 Jun. Gastroenterol Rep (Oxf). 2020. PMID: 32665855 Free PMC article.
Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, Qiu M, Lin R, Zhang H, Lan P, Wu X, Liu G, Wan Y, Liu M, Zhou Z, Huang Y, Li F, Zhang J, Cai Y, Ma T, Zhou J, Wang H, Ling J, Cai Y, Wu Z, Luo S, Ling L, Deng Y. Hu H, et al. Oncologist. 2021 Jan;26(1):e90-e98. doi: 10.1634/theoncologist.2020-0563. Epub 2020 Sep 3. Oncologist. 2021. PMID: 33400355 Free PMC article. Clinical Trial.
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, Hu J, Huang Y, Huang L, Wang H, Shi L, Cai Y, Shen C, Ling J, Xie X, Cai Y, He X, Dou R, Zhou J, Ma T, Zhang X, Luo S, Deng W, Ling L, Liu H, Deng Y. Hu H, et al. Among authors: hu j. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):38-48. doi: 10.1016/S2468-1253(21)00348-4. Epub 2021 Oct 22. Lancet Gastroenterol Hepatol. 2022. PMID: 34688374 Clinical Trial.
mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial.
Shen C, Hu H, Cai Y, Ling J, Zhang J, Wu Z, Xie X, Huang M, Wang H, Kang L, Lan P, Wu X, Liu G, Wan Y, Zhou Z, Huang Y, Li F, Wang H, Ma T, Luo S, Cai Y, Shi L, Deng Y. Shen C, et al. Among authors: hu h. Ann Transl Med. 2022 Feb;10(4):171. doi: 10.21037/atm-21-6731. Ann Transl Med. 2022. PMID: 35280386 Free PMC article.
20,190 results
You have reached the last available page of results. Please see the User Guide for more information.